Skip to main content

Research Repository

Advanced Search

All Outputs (2)

SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia (2023)
Journal Article
Wodi, C., Belali, T., Morse, R., Porazinski, S., & Ladomery, M. (2023). SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia. British Journal of Biomedical Science, 80, 11041. https://doi.org/10.3389/bjbs.2023.11041

Introduction: Dysregulated alternative splicing is a prominent feature of cancer. The inhibition and knockdown of the SR splice factor kinase SRPK1 reduces tumour growth in vivo. As a result several SPRK1 inhibitors are in development including SPHIN... Read More about SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia.

WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1 (2020)
Journal Article
Belali, T., Wodi, C., Clark, B., Cheung, M. K., Craig, T. J., Wheway, G., …Ladomery, M. (2020). WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1. BBA - Gene Regulatory Mechanisms, 1863(12), Article 194642. https://doi.org/10.1016/j.bbagrm.2020.194642

Dysregulated alternative splicing plays a prominent role in all hallmarks of cancer. The splice factor kinase SRPK1 drives the activity of oncogenic splice factors such as SRSF1. SRSF1 in turn promotes the expression of splice isoforms that favour tu... Read More about WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.